Global CNS Therapeutics Industry

LONDON, Jan. 18, 2018 /PRNewswire/ --


Download the full report: https://www.reportbuyer.com/product/1139068



The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World.

Annual estimates and forecasts are provided for the period 2016 through 2024. Also, a five-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs.

The report profiles 162 companies including many key and niche players such as:
- AbbVie Inc.
- Alkermes Plc
- Allergan, Plc
- Amneal Pharmaceuticals, LLC
- AstraZeneca Plc
- BIAL Group



Download the full report: https://www.reportbuyer.com/product/1139068

CNS THERAPEUTICS MCP-1835 A GLOBAL STRATEGIC BUSINESS REPORT CONTENTS

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

Study Reliability and Reporting Limitations
Disclaimers
Data Interpretation & Reporting Level
Quantitative Techniques & Analytics
Product Definitions and Scope of Study
Anti-Alzheimer's Drugs
Anti-Parkinson's Drugs
Anti-Epilepsy Drugs
Pain Management Drugs
Anti-Psychotics Drugs
Bipolar disorder
Schizophrenia
Anti-Depressants Drugs
Others
Attention Deficit Hyperactivity Disorder
Multiple Sclerosis
Insomnia

II. EXECUTIVE SUMMARY

1. INDUSTRY OVERVIEW
CNS Therapeutics Exhibit Robust Opportunities amidst Rising Incidence of CNS Disorders
List of FDA Approved CNS Drugs: 2015 through 2017
Patent Expiries of Major Drugs Exert Downward Pressure on the Global CNS Market
Patent Expiries of Leading CNS Drugs: 2008-2022
Developed Markets to Maintain their Dominance
Developing Market to Drive the Market Momentum

2. MARKET ANALYSIS BY THERAPEUTIC CATEGORIES
Anti-Epilepsy Market
Global Market Overview
Disease Overview
Table 1: Epilepsy Incidence by Type (2016): Percentage Share Breakdown for Idiopathic and Symptomatic Epilepsy (includes corresponding Graph/Chart)
Table 2: Symptomatic Epilepsy Incidence by Type (2016): Percentage Share Breakdown of Congenital, Degenerative, Infective, Neoplastic, Trauma, and Vascular Epilepsy (includes corresponding Graph/Chart)
Treatment
Anti-Epileptic Market (AEDs) by Drug Class: List of Drugs under Broad-Spectrum AEDs and Narrow-Spectrum AEDs
Leading Anti-Epileptic Drugs
Leading Anti-Epileptic Drugs and Their Mechanism of Action
Patent Expiries of Major Anti-Epilepsy Drugs
High Unmet Needs Offer Scope for Market Growth
Select Currently Available Epilepsy Drugs
Select Anti-Epilepsy Drugs (AEDs) in Phase III Trials
Innovative Drugs Needed for Better Treatment Compliance
Abounding Potential for NCEs
Developed Countries Account for a Major Share of Epilepsy Treatment
Developing Countries Struggle with Low Treatment Rates
Refractory Childhood Epilepsy & Pregnancy Epilepsy - Major Concerns
Review of Anti-Epilepsy Drugs
Vimpat®
Keppra®
Lamictal
Tegretol®
Sabril®
Perampanel
Zonegran®
Topamax®
Trileptal®
Neurontin®
Lyrica®
Depakine®
CNS Pain Management
Market Overview
Treatment
Drugs Indicated for Pain Management
Select Phase III Completed Studies for Cancer Pain
Regional Overview
Players
Combination Therapies Gain Prominence
Key Trends in Chronic Pain Management
Minimally Invasive Procedures Gain Popularity for Chronic Back Pain
Neuropathic Pain Management: Market with High Potential
Select Phase III Completed Studies for Neuropathic Pain
Migraine Market: A Core Vertical in CNS Pain Management
Migraine Care: Select Patent Expiries (2013-2015)
New Pain Management Drugs
Recent Approvals in Pain Management: 2016-2017
Select Pain Management Drugs
Flupirtine
Lyrica®
Oxycodone
Nucynta ER
Metabotropic Glutamate Receptors (mGluRs)
Anti-Alzheimer's
Market Overview
Table 3: Alzheimer's Prevalence by Age Group (includes corresponding Graph/Chart)
Treatment for Alzheimer’s
Select Leading Drugs for Alzheimer's Disease by Drug Category
Patent Expiries of Leading Alzheimer’s Drugs
Drug Development Scenario for Alzheimer’s - Major Focus on Amyloid Targets
Aducanumab - A Promising Drug for Alzheimer’s Disease
Phase III Pipeline Drugs for Alzheimer’s Disease
Prevention Gains Increasing Attention
Novel Treatment for Alzheimer’s to Emerge
Evolving Brain Imaging Technologies to Offer Early and Greater Accuracy
A Review of Select Anti-Alzheimer’s Drugs
Aricept
Exelon
Reminyl
Ebixa
Namenda
Anti-Inflammatory Drug, Ponstel, Displays Potential to Treat Alzheimers in Mice
Anti-Parkinson's
Market Overview
Levodopa - The “Gold Standard” for Parkinson’s Treatment
Xadago - New Approved Add-On Therapy for Parkinson’s Disease
NUPLAZID® - The First and the Only Approved Drug for Psychosis related to Parkinson’s disease
MSDC-0160 - A Potential Drug Undergoing Animal Studies
Select Anti-Parkinson’s Drugs
Levodopa
Dopamine Agonists
Mirapex
Requip
Anti-Depressants
Market Overview
Anti-Depressant Treatment
Low R&D Investments Restrict New Antidepressants Development
Select Antidepressants Drugs
Zoloft (Sertraline)
Cymbalta®
Prozac (Fluoxetine)
Effexor (Venlafaxine)
Paxil
Wellbutrin (Bupropion)
Anti-Psychotics
Market Overview
Companies Focus on Next Generation Products to Deflect the Heat of Competition
Leading Atypical Antipsychotics for the Treatment of Schizophrenia
Promising Compounds in Clinical Development for the Treatment of Schizophrenia in Adults
Select Anti-Psychotic Drugs
Zyprexa
Seroquel
Abilify
Clozaril
Risperdal
Risperdal® Consta®
Geodon
Invega Sustenna
Saphris
Latuda
Other CNS Disorders (ADHD, MS, and Insomnia)
Attention Deficit Hyperactivity Disorder (ADHD)
Market Overview
Approved Drugs for ADHD: 2017
Pipeline Drugs for ADHD: As of March 2017
Select ADHD Drugs
Concerta
Adderall
Multiple Sclerosis (MS)
Multiple Sclerosis Approved Therapies (Injectables)
Multiple Sclerosis Approved Therapies (Oral)
Patent Expiration Date/Year of the Major MS Drugs
Ocrevus - The First Approved Drug for Primary Progressive Multiple Sclerosis (PPMS)
Multiple Sclerosis: Pipeline Analysis
Potential MS treatments, which are currently in Phase 3 Clinical Trials
Potential MS treatments, which are currently in Phase 2 Clinical Trials
Potential Treatment for Primary Progressive MS, which are in Phase 3
Potential Treatment for Primary Progressive MS, which are in Phase 2
Potential Treatment for Secondary Progressive MS, which are in Phase 3
Potential Treatment for Secondary Progressive MS, Which are in Phase 2
Insomnia
Overview
Zolpidem
Eszopiclone

3. GROWTH DRIVERS & MARKET TRENDS
Burgeoning Global Aging Populace, Longer Life Expectancy to Drive CNS Demand
Table 4: Aging Population by Age Group in More Developed Countries (1975-2050) (includes corresponding Graph/Chart)
Table 5: Global Population Statistics for the 65+ Age Group (2016) (includes corresponding Graph/Chart)
Table 6: Life Expectancy for Select Countries in Number of Years: 2016 (includes corresponding Graph/Chart)
Increased Spending on Prescription Drugs Bodes Well for the CNS Therapeutics Market
Rising Healthcare Expenditure to Boost CNS Therapeutics Market
Table 7: Healthcare Spending as a Percentage of GDP by Region (2016) (includes corresponding Graph/Chart)
Table 8: Healthcare Spending as a Percentage of GDP in Select Countries (2013) (includes corresponding Graph/Chart)
Table 9: Global Middle Class Population (in Millions) by Geographic Region: 2010, 2020P & 2030P (includes corresponding Graph/Chart)
Table 10: Annual Disposable Incomes in US$ Thousand for Select Countries (2012) (includes corresponding Graph/Chart)
Growing Penetration of Generic Drugs Emerges as a Key Trait
Table 11: Global Spending on Generic Drugs Vis-à-vis Branded Drugs (2013 & 2018): Percentage Share Breakdown of Dollar Spending by Drug Category (includes corresponding Graph/Chart)
Developments in CNS Drug Delivery Technologies Bode Well for the CNS Drugs Market
Understanding of BBB Cell Biology & Its Positive Impact on Epilepsy Drugs: A Case-in-Point
Pharma Companies: Seeking New Tools to Offset Pressure on Drug Pipelines
Awareness Campaigns Launched by Pharma Companies to Benefit the Market
Music and Memory Programs Positively Impact Alzheimer’s Disease (AD) and Related Dementia (ADRD) Patients
New Method to Isolate Active Compounds Related to Alzheimers from Plant Medicines

4. PRODUCT OVERVIEW
Definition
Central Nervous System
Mortality Threat of CNS Disorders
Science of NMDA Receptors and its Disease Significance
Major CNS Disorders:
Alzheimer’s Disease
Alzheimer’s Effect on Brain
Causes for Alzheimer’s
Who Are at Risk?
Prevalence of Alzheimer’s Disease
Diagnosis of Alzheimer’s
Parkinson’s Disease
Prevalence
Symptoms
Causes
Diagnosis
Epilepsy
Symptoms of Epilepsy
Types of Epilepsy and Epileptic Seizures
Preventive Measures
Treatment Options for Epilepsy Patients
Treatment Options Available for Epilepsy Patients
Epilepsy Drug Treatment Paradigm
Pain Management
Debilitating Effects of Pain
Types of Pain
Acute Pain
Chronic Pain
Migraine
Neuropathic Pain
Nociceptive Pain
Anti-Psychotics
Bipolar Disorder
Symptoms of Bipolar Disorder
Mood Episode - A Major Symptom
Manic Episode Vs Depressive Episode
Causes of Bipolar Disorder
Types of Bipolar Disorder
Co-morbidities of Bipolar Disorder
Schizophrenia
Prevalence by Gender
Symptoms of Schizophrenia
Causes of Schizophrenia
Therapies for Bipolar Disorder & Schizophrenia
Mood Stabilizing Agents
Antidepressants
Antipsychotic Drugs
Indications of Antipsychotics
An Effective Adjunctive Therapy
Off-label Uses
Efficacy - Marred by Lack of Evidence Base
Types of Antipsychotics
Difference between Typical and Atypical
Atypical Antipsychotics Up Against Typicals
Side Effects of Antipsychotics
Symptoms of Antipsychotics Withdrawal
Controversies Surrounding Antipsychotics
Prohibited Practices
Antipsychotics in Pregnant Women
Depression
Prevalence of Depression
Causes of Depression
Types of Depressive Disorders
Available Treatment
Tricyclic Antidepressants
Monoamine Oxidase Inhibitors
Lithium Salts
Working of Antidepressants
Ranking of Antidepressants in Terms of Efficacy
Types of Antidepressants
NMDA Receptor Antagonists
NMDA Receptor (NMDAR)
NMDA Receptor Agonists
Acetylcholinesterase Inhibitors
Selective Serotonin Reuptake Inhibitors (SSRIs)
Workings of SSRIs
Safety Levels of SSRI Drugs
Adverse Effects of SSRI
Serotonin Noradrenaline Reuptake Inhibitors (SNRIs)
Others Common CNS Disorders
Attention Deficit Hyperactivity Disorder
Consequences of ADHD
What Leads to ADHD?
Treating ADHD
Multiple Sclerosis (MS)
Types of Multiple Sclerosis
Table 12: Clinical Subtypes of Multiple Sclerosis (MS) (includes corresponding Graph/Chart)
Prevalence of MS
Causes of MS
Myths Surrounding Multiple Sclerosis
Symptoms of MS
Diagnosis of MS
Treatment
Insomnia
Prevalence of Insomnia
Therapies for Insomnia

5. INNOVATIONS
Scientists Discover New Epilepsy Drug in Fish Model
A Smart Walking Stick for Parkinson’s Patients
New Technologies for Pain Management - A Threat to Opiod Therapeutics
Radiofrequency Ablation Device
Omron Healthcare’s HEAT Pain Pro™ TENS Device
BurstDR Stimulation from St Jude Medical, Inc
Virtual Reality from DeepStream VR
ActiPatch® from BioElectronics Corporation

6. PRODUCT INTRODUCTIONS/INNOVATIONS & R&D BREAKTHROUGHS
Zydus Cadila's Anti-Depressant Drug Receives USFDA Approval
Neurocrine’s 80 mg INGREZZA Capsules gets FDA Approval
Roche’s OCREVUS gets Swiss Agency Approval
Theranexus’S THN102 Drug Receives US Patent
UCB’s AED VIMPAT gets EU Approval for Paediatric Use
UCB’s AED BRIVIACT Receives Approval from FDA
Dr Reddy’s Unveils Anti-Depressant & Muscle Relaxant Drugs
Sunovion Submits Drug Application to the FDA for Dasotraline
Eisai Pharmaceuticals Unveils Anti-Epilepsy Drug Fycompa
Eisai's Antiepileptic Drug gets Approval from FDA
UCB’s AED gets EU CHMP Positive Opinion on License Extension
Prexton Unveils Phase II Clinical Testing of its Investigational Drug Candidate in PD
BIAL Introduces New Treatment Opicapone for Parkinson's Disease
Sunovion’s Latuda Receives FDA Approval to Treat Bipolar Depression
Alkermes gets FDA Approval for Two-Month ARISTADA
Lundbeck & Otsuka’s Brexpiprazole gets Approval from EMA
Sumitomo Dainippon Pharma gets Import Drug License Approval from CFDA
Minoryx’s MIN-102 gets Orphan Drug Designation by FDA
Sunovion’s Latuda gets FDA Approval
Tohoku University Introduces New Drug SAK3
FYCOMPA® of Eisai Receives FDA Approval
Proximagen Announces the Meeting of Primary Efficacy Endpoint for Midazolam Nasal Spray
GW Pharmaceuticals Announces Positive Results for Second Phase III Study of Epidiolex
Daiichi Sankyo Reports Results of Two Pain Drugs
Sumitomo Dainippon Pharma Declares Topline Results for Lurasidone from a Phase 3 Study
Ocrevus Receives FDA Approval
FDA Scrutinizes Skin Reactions with Zecuity Sumatriptan Patch
Zinbryta Receives FDA Approval for Treating Multiple Sclerosis
Tecfidera Emerges as a First-line Treatment for Relapsing- remitting Multiple Sclerosis (RRMS)
GlaxoSmithKline Announces the Discontinuation of Retigabine ( Trobalt)
EISAI’S BACE Inhibitor E2609 gets Fast Track Designation from FDA
Cleveland Clinic Lerner College of Medicine Unveils NTRX-07
BIAL Introduces Opicapone
iX Biopharma Unveils Next Drug BnoX
Daiichi Sankyo & UCB Unveils Vimpat Tablets
AstraZeneca & Lilly’s AZD3293 gets FDA Fast Track Designation
Eisai Introduces Fycompa (perampanel)
Novartis Drug Afinitor gets EU Approval
TG Therapeutics to Start Phase 2 Clinical Study of TG-1101
Acadia gets FDA Approval for the Nuplazid (pimavanserin) Drug
AstraZeneca & Lilly’s AZD3293 Continues into Phase III of the Phase II/III Seamless Trial
Zambon S.p.A and Newron Unveils Xadago (safinamide)
Lundbeck and Takeda gets CRL from FDA for Brintellix ( vortioxetine) sNDA
Allergan Announces Availabilty of VRAYLAR in the US
Otsuka’s gets Approval for ABILIFY
Zambon and Newron Unveils Xadago (safinamide)
UCB gets EU Approval for New Epilepsy Drug BRIVIACT

7. RECENT INDUSTRY ACTIVITY
Mylan Acquires Meda
ProQR Splits Out Amylon Therapeutics for CNS Therapeutics
Allergan Takes Over Lysosomal Therapeutics
AstraZeneca Partners with Takeda
Charles River Takes Over Brains On-Line
Pairnomix Partners with StemoniX to Develop Epilepsy Model
Accera Inks Partnership & Licensing Agreement with DuChemBioH
H. Lundbeck A/S Inks Agreement with IBC
Xenon Takes Over XEN1101
Bristol-Myers Squibb Inks Two Separate Agreement with Biogen & Roche
Valeo Pharma Partners with Zambon
Sumitomo Dainippon Pharma Inks License Agreement with Bukwang
Eisai Inks Agreement with Meiji Seika Pharma
Actavis UK & Ireland Taken Over by Accord Healthcare
Piramal Takes Over Mallinckrodt
Ataxion Takes Over Luc Therapeutics
Otsuka to Take Over Neurovance
nLife Partners with wave life sciences
EISAI Inks Marketing and Distribution Agreement with Orion
Sumitomo Dainippon Pharma Takes Over Tolero
Zydus Cadila Takes Over Sentynl
Takeda Partners with Ovid
Lilly toTake Over CoLucid
Aurobindo Pharma Takes Over Generis
Genkyotex Merges with Genticel
Eisai Inks Agreement with Keio University
Evotec Partners with Celgene
AstraZeneca Inks Agreement with Lilly
Takeda and Lightstone Introduces Cerevance
Pacira Partners with GeneAlign
Allergan Takes Over Chase Pharmaceuticals
Synapcell Partners with University of Utah
BlackThorn Therapeutics to Develop Novel
Evotec Partners with UCB
Ligand Enters License Agreement with Seelos Therapeutics
Takeda Partners with Affilogic
Riemser Takes Over CNS Portfolio from Dolorgiet
OPKO Takes Over Transition Therapeutics, Inc
Sunovion to Take Over Cynapsus Therapeutics
Boehringer Ingelheim Partners with Saniona
Denali Partners with F-star Modular Antibody Technology
Scintilla Takes Over Semnur Pharmaceuticals
Pfizer Takes Over Bamboo Therapeutics
Pfizer Partners with IBM
Lupin Acquires 21 Branded Drugs from Shionogi
Teva Takes Over Actavis Generics
Chronos Takes Over Pre-clinical Programmes from Shire
Otsuka & IBM Inks Agreement to Establish Otsuka Digital Health
Aspen Inks Agreement with AstraZeneca AB and AstraZeneca UK
Merck Acquires Afferent Pharmaceuticals
Centrexion Takes Over three Analgesic Candidates from Boehringer Ingelheim
Reset Partners with Alkermes
Zambon & Newron Pharmaceuticals Expands its Market
Eisai Inks Agreement with Esteve
Upsher-Smith Partners with Saniona
Acorda Agrees to Take Over Biotie Therapies
Eisai Inks Agreement with Sysmex
UCB Inks Agreement with Baylor College
GTCR Partners with Ed Fiorentino
Boehringer Ingelheim Inks Agreement with Arena
PsychoGenics Partners with ADDF
Takeda Inks Agreement with NsGene

8. FOCUS ON SELECT GLOBAL PLAYERS
AbbVie Inc. (USA)
Alkermes Plc. (Ireland)
Allergan, Plc (Ireland)
Amneal Pharmaceuticals, LLC (USA)
AstraZeneca Plc (UK)
BIAL Group (Portugal)
Bristol-Myers Squibb (USA)
Eisai Co., Ltd. (Japan)
Endo Pharmaceuticals Inc. (USA)
Eli Lilly and Co. (USA)
F. Hoffmann-La Roche Ltd. (Switzerland)
Fabre-Kramer Pharmaceuticals, Inc. (USA)
GlaxoSmithKline (UK)
H. Lundbeck A/S (Denmark)
Johnson & Johnson (USA)
Janssen Pharmaceuticals, Inc. (USA)
Merck & Co., Inc. (USA)
Neurocrine Biosciences, Inc. (USA)
Novartis AG (Switzerland)
Otsuka Pharmaceutical Co., Ltd. (Japan)
Pfizer, Inc. (USA)
Purdue Pharma L.P. (USA)
Sanofi S.A (France)
Shire Plc (UK)
Strides Shasun Limited (India)
Sumitomo Dainippon Pharma Co., Ltd. (Japan)
Sunovion Pharmaceuticals, Inc. (USA)
Takeda Pharmaceutical Co., Ltd. (Japan)
Teva Pharmaceutical Industries Ltd. (Israel)
UCB Group (Belgium)

9. GLOBAL MARKET PERSPECTIVE
Table 13: World Recent Past, Current & Future Analysis for CNS Therapeutics by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, Latin America and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)
Table 14: World Historic Review for CNS Therapeutics by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, Latin America and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
Table 15: World 14-Year Perspective for CNS Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for US, Canada, Japan, Europe, Asia-Pacific, Latin America and Rest of World Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart)
Table 16: World Recent Past, Current & Future Analysis for Anti-Alzheimer’s by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, Latin America and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)
Table 17: World Historic Review for Anti-Alzheimer’s by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, Latin America and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
Table 18: World 14-Year Perspective for Anti-Alzheimer’s by Geographic Region - Percentage Breakdown of Value Sales for US, Canada, Japan, Europe, Asia-Pacific, Latin America and Rest of World Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart)
Table 19: World Recent Past, Current & Future Analysis for Anti-Parkinson’s by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, Latin America and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)
Table 20: World Historic Review for Anti-Parkinson’s by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, Latin America and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
Table 21: World 14-Year Perspective for Anti-Parkinson’s by Geographic Region - Percentage Breakdown of Value Sales for US, Canada, Japan, Europe, Asia-Pacific, Latin America and Rest of World Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart)
Table 22: World Recent Past, Current & Future Analysis for Anti-Epilepsy by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, Latin America and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)
Table 23: World Historic Review for Anti-Epilepsy by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, Latin America and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
Table 24: World 14-Year Perspective for Anti-Epilepsy by Geographic Region - Percentage Breakdown of Value Sales for US, Canada, Japan, Europe, Asia-Pacific, Latin America and Rest of World Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart)
Table 25: World Recent Past, Current & Future Analysis for Pain Management by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, Latin America and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)
Table 26: World Historic Review for Pain Management by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, Latin America and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
Table 27: World 14-Year Perspective for Pain Management by Geographic Region - Percentage Breakdown of Value Sales for US, Canada, Japan, Europe, Asia-Pacific, Latin America and Rest of World Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart)
Table 28: World Recent Past, Current & Future Analysis for Anti-Psychotics by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, Latin America and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)
Table 29: World Historic Review for Anti-Psychotics by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, Latin America and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
Table 30: World 14-Year Perspective for Anti-Psychotics by Geographic Region - Percentage Breakdown of Value Sales for US, Canada, Japan, Europe, Asia-Pacific, Latin America and Rest of World Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart)
Table 31: World Recent Past, Current & Future Analysis for Anti-Depressants by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, Latin America and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)
Table 32: World Historic Review for Anti-Depressants by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, Latin America and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
Table 33: World 14-Year Perspective for Anti-Depressants by Geographic Region - Percentage Breakdown of Value Sales for US, Canada, Japan, Europe, Asia-Pacific, Latin America and Rest of World Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart)
Table 34: World Recent Past, Current & Future Analysis for Others by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, Latin America and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)
Table 35: World Historic Review for Others by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, Latin America and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
Table 36: World 14-Year Perspective for Others by Geographic Region - Percentage Breakdown of Value Sales for US, Canada, Japan, Europe, Asia-Pacific, Latin America and Rest of World Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart)

III. MARKET

1. THE UNITED STATES
A.Market Analysis
The Largest CNS Therapeutics Market Globally
Patent Expiries of Leading CNS Drugs in the US
Aging Population: A Strong Demographic Driver
Table 37: North American Elderly Population by Age Group (1975-2050) (includes corresponding Graph/Chart)
Table 38: Aging Population in the US (2015 & 2030): 60 Years and Above Population (in Thousands) and Percentage of Population (includes corresponding Graph/Chart)
Focus on Select Markets
Alzheimer’s Market
Anti-depressant Drugs
Usage of Antidepressants Surges in the US
Anti-Epilepsy Market
Epilepsy - A Major Concern for the Healthcare Industry
A Glance at Epilepsy Statistics
Anti-Epilepsy Drugs
The US Epilepsy Market: Patent Expiry of Select Major Drugs
Epilepsy in Children
Growing Competition from Generics
Pain Management Market
Consumers in the US Seek Different Options for Chronic Pain Management
Neuropathic Pain Market
Anti-Psychotic Drugs Market
Mental Illnesses - Epidemiology
Facts & Figures
Table 39: Lifetime Prevalence (%) of Bipolar Disorder in the US Population by Age Group (includes corresponding Graph/Chart)
Popular Antipsychotic Drugs in the US
Anti-Psychotic Drugs by FDA Approved Age and Indication in the US
Table 40: The US Anti-Psychotic Drugs Market (2016): Percentage Share Breakdown of Value Sales by Indication (includes corresponding Graph/Chart)
Surging Off-label Prescriptions
Generics Occupy Front Seat
Rising Antipsychotic Use among Children - A Cause of Concern
ADHD Market
Select Available ADHD Drugs in the US
Table 41: The US ADHD Drugs Market by Drug Category (2016): Percentage Share Breakdown of Total Prescription Sales for Stimulants (Amphetamines and Methylphenidates) and Non-Stimulants (includes corresponding Graph/Chart)
Table 42: The US ADHD Drugs Market by Type (2016): Percentage Share Breakdown of Total Prescription Sales for Branded & Generic Drug Groups (includes corresponding Graph/Chart)
Adult ADHD Drugs Continue to Widen their Share
Table 43: The US ADHD Drugs Market by Drug Category (2016): Percentage Share Breakdown of Total Prescriptions for Adult & Pediatric Patient Groups (includes corresponding Graph/Chart)
Product Launches
Strategic Corporate Developments
Select Key Players
B.Market Analytics
Table 44: The US Recent Past, Current & Future Analysis for CNS Therapeutics by Product Segment - Anti-Alzheimer's, Anti-Parkinson's, Anti-Epilepsy, Pain Management, Anti-Psychotics, Anti-Depressants, and Other Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)
Table 45: The US Historic Review for CNS Therapeutics by Product Segment - Anti-Alzheimer's, Anti-Parkinson's, Anti-Epilepsy, Pain Management, Anti-Psychotics, Anti-Depressants, and Other Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
Table 46: The US 14-Year Perspective for CNS Therapeutics by Product Segment - Percentage Breakdown of Dollar Sales for Anti-Alzheimer's, Anti-Parkinson's, Anti-Epilepsy, Pain Management, Anti-Psychotics, Anti-Depressants, and Other Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart)

2. CANADA
A.Market Analysis
CNS Diseases: Facts & Figures
Strategic Corporate Developments
B.Market Analytics
Table 47: Canadian Recent Past, Current & Future Analysis for CNS Therapeutics by Product Segment - Anti-Alzheimer's, Anti-Parkinson's, Anti-Epilepsy, Pain Management, Anti-Psychotics, Anti-Depressants, and Other Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)
Table 48: Canadian Historic Review for CNS Therapeutics by Product Segment - Anti-Alzheimer's, Anti-Parkinson's, Anti-Epilepsy, Pain Management, Anti-Psychotics, Anti-Depressants, and Other Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
Table 49: Canadian 14-Year Perspective for CNS Therapeutics by Product Segment - Percentage Breakdown of Dollar Sales for Anti-Alzheimer's, Anti-Parkinson's, Anti-Epilepsy, Pain Management, Anti-Psychotics, Anti-Depressants, and Other Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart)

3. JAPAN
A.Market Analysis
Product Launches
Strategic Corporate Developments
Select Key Players
B.Market Analytics
Table 50: Japanese Recent Past, Current & Future Analysis for CNS Therapeutics by Product Segment - Anti-Alzheimer's, Anti-Parkinson's, Anti-Epilepsy, Pain Management, Anti-Psychotics, Anti-Depressants, and Other Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)
Table 51: Japanese Historic Review for CNS Therapeutics by Product Segment - Anti-Alzheimer's, Anti-Parkinson's, Anti-Epilepsy, Pain Management, Anti-Psychotics, Anti-Depressants, and Other Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
Table 52: Japanese 14-Year Perspective for CNS Therapeutics by Product Segment - Percentage Breakdown of Dollar Sales for Anti-Alzheimer's, Anti-Parkinson's, Anti-Epilepsy, Pain Management, Anti-Psychotics, Anti-Depressants, and Other Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart)

4. EUROPE
A.Market Analysis
Ageing Population Boosts Demand
Table 53: European Country-wise Statistics of 65+ Population as % of Total Population: As on January 1, 2015 (includes corresponding Graph/Chart)
European Patent Expiries of Select CNS Drugs
Pain Management Market
Neuropathic Pain Market Witnesses Foray of Generics
Anti-Psychotics Market
Demand for Antipsychotics for Bipolar Disorder Upbeat
Strategic Corporate Development
B.Market Analytics
Table 54: European Recent Past, Current & Future Analysis for CNS Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets Independently Analyzed with Annual Sales in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)
Table 55: European Historic Review for CNS Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets Independently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
Table 56: European Recent Past, Current & Future Analysis for CNS Therapeutics by Product Segment - Anti-Alzheimer's, Anti-Parkinson's, Anti-Epilepsy, Pain Management, Anti-Psychotics, Anti-Depressants, and Other Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)
Table 57: European Historic Review for CNS Therapeutics by Product Segment - Anti-Alzheimer's, Anti-Parkinson's, Anti-Epilepsy, Pain Management, Anti-Psychotics, Anti-Depressants, and Other Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
Table 58: European 14-Year Perspective for CNS Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart)
Table 59: European 14-Year Perspective for CNS Therapeutics by Product Segment - Percentage Breakdown of Dollar Sales for Anti-Alzheimer's, Anti-Parkinson's, Anti-Epilepsy, Pain Management, Anti-Psychotics, Anti-Depressants, and Other Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart)

4a. FRANCE
A.Market Analysis
Product Launch
Strategic Corporate Developments
Sanofi - A Key French Player
B.Market Analytics
Table 60: French Recent Past, Current & Future Analysis for CNS Therapeutics by Product Segment - Anti-Alzheimer's, Anti-Parkinson's, Anti-Epilepsy, Pain Management, Anti-Psychotics, Anti-Depressants, and Other Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)
Table 61: French Historic Review for CNS Therapeutics by Product Segment - Anti-Alzheimer's, Anti-Parkinson's, Anti-Epilepsy, Pain Management, Anti-Psychotics, Anti-Depressants, and Other Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
Table 62: French 14-Year Perspective for CNS Therapeutics by Product Segment - Percentage Breakdown of Dollar Sales for Anti-Alzheimer's, Anti-Parkinson's, Anti-Epilepsy, Pain Management, Anti-Psychotics, Anti-Depressants, and Other Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart)

4b. GERMANY
A.Market Analysis
Strategic Corporate Developments
B.Market Analytics
Table 63: German Recent Past, Current & Future Analysis for CNS Therapeutics by Product Segment - Anti-Alzheimer's, Anti-Parkinson's, Anti-Epilepsy, Pain Management, Anti-Psychotics, Anti-Depressants, and Other Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)
Table 64: German Historic Review for CNS Therapeutics by Product Segment - Anti-Alzheimer's, Anti-Parkinson's, Anti-Epilepsy, Pain Management, Anti-Psychotics, Anti-Depressants, and Other Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
Table 65: German 14-Year Perspective for CNS Therapeutics by Product Segment - Percentage Breakdown of Dollar Sales for Anti-Alzheimer's, Anti-Parkinson's, Anti-Epilepsy, Pain Management, Anti-Psychotics, Anti-Depressants, and Other Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart)

4c. ITALY
A.Market Analysis
Market Snapshots
B.Market Analytics
Table 66: Italian Recent Past, Current & Future Analysis for CNS Therapeutics by Product Segment - Anti-Alzheimer's, Anti-Parkinson's, Anti-Epilepsy, Pain Management, Anti-Psychotics, Anti-Depressants, and Other Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)
Table 67: Italian Historic Review for CNS Therapeutics by Product Segment - Anti-Alzheimer's, Anti-Parkinson's, Anti-Epilepsy, Pain Management, Anti-Psychotics, Anti-Depressants, and Other Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
Table 68: Italian 14-Year Perspective for CNS Therapeutics by Product Segment - Percentage Breakdown of Dollar Sales for Anti-Alzheimer's, Anti-Parkinson's, Anti-Epilepsy, Pain Management, Anti-Psychotics, Anti-Depressants, and Other Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart)

4d. THE UNITED KINGDOM
A.Market Analysis
NICE Recommendations On CNS Therapeutics
Product Launches
Strategic Corporate Developments
Select Key Players
B.Market Analytics
Table 69: The UK Recent Past, Current & Future Analysis for CNS Therapeutics by Product Segment - Anti-Alzheimer's, Anti-Parkinson's, Anti-Epilepsy, Pain Management, Anti-Psychotics, Anti-Depressants, and Other Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)
Table 70: The UK Historic Review for CNS Therapeutics by Product Segment - Anti-Alzheimer's, Anti-Parkinson's, Anti-Epilepsy, Pain Management, Anti-Psychotics, Anti-Depressants, and Other Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
Table 71: The UK 14-Year Perspective for CNS Therapeutics by Product Segment - Percentage Breakdown of Dollar Sales for Anti-Alzheimer's, Anti-Parkinson's, Anti-Epilepsy, Pain Management, Anti-Psychotics, Anti-Depressants, and Other Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart)

4e. SPAIN
A.Market Analysis
Product Launches
Strategic Corporate Development
B.Market Analytics
Table 72: Spanish Recent Past, Current & Future Analysis for CNS Therapeutics by Product Segment - Anti-Alzheimer's, Anti-Parkinson's, Anti-Epilepsy, Pain Management, Anti-Psychotics, Anti-Depressants, and Other Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)
Table 73: Spanish Historic Review for CNS Therapeutics by Product Segment - Anti-Alzheimer's, Anti-Parkinson's, Anti-Epilepsy, Pain Management, Anti-Psychotics, Anti-Depressants, and Other Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
Table 74: Spanish 14-Year Perspective for CNS Therapeutics by Product Segment - Percentage Breakdown of Dollar Sales for Anti-Alzheimer's, Anti-Parkinson's, Anti-Epilepsy, Pain Management, Anti-Psychotics, Anti-Depressants, and Other Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart)

4f. RUSSIA
Market Analysis
Table 75: Russian Recent Past, Current & Future Analysis for CNS Therapeutics by Product Segment - Anti-Alzheimer's, Anti-Parkinson's, Anti-Epilepsy, Pain Management, Anti-Psychotics, Anti-Depressants, and Other Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)
Table 76: Russian Historic Review for CNS Therapeutics by Product Segment - Anti-Alzheimer's, Anti-Parkinson's, Anti-Epilepsy, Pain Management, Anti-Psychotics, Anti-Depressants, and Other Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
Table 77: Russian 14-Year Perspective for CNS Therapeutics by Product Segment - Percentage Breakdown of Dollar Sales for Anti-Alzheimer's, Anti-Parkinson's, Anti-Epilepsy, Pain Management, Anti-Psychotics, Anti-Depressants, and Other Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart)

4g. REST OF EUROPE
A.Market Analysis
Product Launches
Strategic Corporate Developments
Select Key Players
B.Market Analytics
Table 78: Rest of Europe Recent Past, Current & Future Analysis for CNS Therapeutics by Product Segment - Anti-Alzheimer's, Anti-Parkinson's, Anti-Epilepsy, Pain Management, Anti-Psychotics, Anti-Depressants, and Other Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)
Table 79: Rest of Europe Historic Review for CNS Therapeutics by Product Segment - Anti-Alzheimer's, Anti-Parkinson's, Anti-Epilepsy, Pain Management, Anti-Psychotics, Anti-Depressants, and Other Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
Table 80: Rest of Europe 14-Year Perspective for CNS Therapeutics by Product Segment - Percentage Breakdown of Dollar Sales for Anti-Alzheimer's, Anti-Parkinson's, Anti-Epilepsy, Pain Management, Anti-Psychotics, Anti-Depressants, and Other Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart)

5. ASIA-PACIFIC
A.Market Analysis
India & China Offer Significant Growth Opportunities
Table 81: China and India Lead Global Population (2015): Table Depicting China and India’s Huge Population Vis-a-vis Other Countries’ Population (in Millions) by Age Group (includes corresponding Graph/Chart)
Growing Antipsychotics Market in Asia
China: The Primary Market for CNS Drugs in Asia-Pacific
Select Anti-Schizophrenia Drugs Available in China
Other Available CNS Drugs in China
Product Launches
Strategic Corporate Developments
Strides Shasun Limited - A Key Indian Player
B.Market Analytics
Table 82: Asia-Pacific Recent Past, Current & Future Analysis for CNS Therapeutics by Geographic Region - China, India and Rest of Asia-Pacific Markets Independently Analyzed with Annual Sales in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)
Table 83: Asia-Pacific Historic Review for CNS Therapeutics by Geographic Region - China, India and Rest of Asia-Pacific Markets Independently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
Table 84: Asia-Pacific Recent Past, Current & Future Analysis for CNS Therapeutics by Product Segment - Anti-Alzheimer's, Anti-Parkinson's, Anti-Epilepsy, Pain Management, Anti-Psychotics, Anti-Depressants, and Other Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)
Table 85: Asia-Pacific Historic Review for CNS Therapeutics by Product Segment - Anti-Alzheimer's, Anti-Parkinson's, Anti-Epilepsy, Pain Management, Anti-Psychotics, Anti-Depressants, and Other Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
Table 86: Asia-Pacific 14-Year Perspective for CNS Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for China, India and Rest of Asia-Pacific Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart)
Table 87: Asia-Pacific 14-Year Perspective for CNS Therapeutics by Product Segment - Percentage Breakdown of Dollar Sales for Anti-Alzheimer's, Anti-Parkinson's, Anti-Epilepsy, Pain Management, Anti-Psychotics, Anti-Depressants, and Other Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart)

6. LATIN AMERICA
Market Analysis
Table 88: Latin American Recent Past, Current & Future Analysis for CNS Therapeutics by Geographic Region - Brazil and Rest of Latin America Markets Independently Analyzed with Annual Sales in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)
Table 89: Latin American Historic Review for CNS Therapeutics by Geographic Region - Brazil and Rest of Latin America Markets Independently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
Table 90: Latin American Recent Past, Current & Future Analysis for CNS Therapeutics by Product Segment - Anti-Alzheimer's, Anti-Parkinson's, Anti-Epilepsy, Pain Management, Anti-Psychotics, Anti-Depressants, and Other Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)
Table 91: Latin American Historic Review for CNS Therapeutics by Product Segment - Anti-Alzheimer's, Anti-Parkinson's, Anti-Epilepsy, Pain Management, Anti-Psychotics, Anti-Depressants, and Other Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
Table 92: Latin American 14-Year Perspective for CNS Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Brazil and Rest of Latin America Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart)
Table 93: Latin American 14-Year Perspective for CNS Therapeutics by Product Segment - Percentage Breakdown of Dollar Sales for Anti-Alzheimer's, Anti-Parkinson's, Anti-Epilepsy, Pain Management, Anti-Psychotics, Anti-Depressants, and Other Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart)

7. REST OF WORLD
A.Market Analysis
Teva Pharmaceutical Industries Ltd. - A Key Israeli Company
B.Market Analytics
Table 94: Rest of World Recent Past, Current & Future Analysis for CNS Therapeutics by Product Segment - Anti-Alzheimer's, Anti-Parkinson's, Anti-Epilepsy, Pain Management, Anti-Psychotics, Anti-Depressants, and Other Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)
Table 95: Rest of World Historic Review for CNS Therapeutics by Product Segment - Anti-Alzheimer's, Anti-Parkinson's, Anti-Epilepsy, Pain Management, Anti-Psychotics, Anti-Depressants, and Other Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
Table 96: Rest of World 14-Year Perspective for CNS Therapeutics by Product Segment - Percentage Breakdown of Dollar Sales for Anti-Alzheimer's, Anti-Parkinson's, Anti-Epilepsy, Pain Management, Anti-Psychotics, Anti-Depressants, and Other Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart)

IV. COMPETITIVE LANDSCAPE

Total Companies Profiled: 162 (including Divisions/Subsidiaries - 183) The United States (79) Canada (13) Japan (15) Europe (50) - France (5) - Germany (9) - The United Kingdom (9) - Italy (2) - Spain (3) - Rest of Europe (22) Asia-Pacific (Excluding Japan) (19) Middle East (4) Latin America (1) Africa (2)
Download the full report: https://www.reportbuyer.com/product/1139068

About Reportbuyer
Reportbuyer is a leading industry intelligence solution that provides all market research reports from top publishers

For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: [email protected]
Tel: +1 (718) 213 4904
Website: www.reportbuyer.com

SOURCE ReportBuyer

Related Links

http://www.reportbuyer.com